Free Trial
→ SpaceX will crumble without these 5 companies (From InvestPub) (Ad)tc pixel
NASDAQ:TAOX

Synaptogenix Q3 2025 Earnings Report

Synaptogenix logo
$3.62 0.00 (0.00%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$3.64 +0.02 (+0.69%)
As of 06/12/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Synaptogenix EPS Results

Actual EPS
-$1.56
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Synaptogenix Revenue Results

Actual Revenue
$2.41 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Synaptogenix Announcement Details

Quarter
Q3 2025
Date
11/14/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Synaptogenix Earnings Headlines

Synaptogenix (NASDAQ:TAOX) Shares Down 3.4% - Here's What Happened
June 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30830362
TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation
November 18, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-and-yuma-asset-management-to-host-livestream-on-x-bittensor-tao-and-deai-innovation-302618425.html
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. Elon believes what Michael Robinson calls 'Project Unlimited' could unlock $100 trillion in potential growth. One little-known company sits at the center of it all, and most investors have no idea it exists. Position yourself before this company potentially hits the front page.tc pixel
June 15 at 1:00 AM  |  Weiss Ratings (Ad)
Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys
November 11, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tradr-set-to-debut-etfs-targeting-bloom-energy-celestica-nano-nuclear-and-synopsys-302611818.html
TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds
November 4, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-announces-initial-750-000-investment-in-yuma-asset-managements-subnet-funds-302603960.html
TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency
October 20, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tao-synergies-raises-bittensor-tao-holdings-to-over-54-000-tokens-largest-publicly-traded-holder-of-top-decentralized-ai-cryptocurrency-302589032.html
See More Synaptogenix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synaptogenix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synaptogenix and other key companies, straight to your email.

About Synaptogenix

Synaptogenix (NASDAQ:TAOX) operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

View Synaptogenix Profile
Earnings Tools